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Abstract: An effective treatment for metastatic melanoma remains one of the most elusive goals 
in all of oncology. Several generations of therapeutic trials have yet to yield any agents that can 
signiﬁ  cantly prolong survival for widespread disease. Despite this disheartening history, our 
understanding of the biology and molecular genetics of melanoma hold the promise of a new era 
of molecular targets. One pathway that appears to be universally activated in and critically 
needed for melanoma growth is the Ras/mitogen activated protein (MAP) kinase signaling 
cascade. Since the enzymatic functions of the signaling partners are well characterized, this 
pathway offers many potential “druggable” candidates including Braf, Mek and Ras itself. In 
this review, we describe this pathway in the context of melanoma tumorigenesis and discuss 
some of the current relevant pharmacologic treatments and clinical trials.
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Introduction
The incidence of malignant melanoma in Western countries is increasing at an alarming 
rate and has become a major public health concern. In the United States the incidence 
has risen by 619% from 1950 to 2000 (Tsao, Atkins et al 2004). In 2007, there will 
be an estimated 59,940 cases of melanoma with 8,110 deaths (Jemal et al 2007); 
although this represents a slight drop in the incidence of melanoma, recalibration of 
the statistical methodology (Pickle et al 2007) in the U.S. may in fact account for the 
apparent decline. Fortunately, in spite of the aforementioned estimates, more people 
diagnosed with melanoma are surviving longer. This improved survival is essentially 
due to early detection and surgery. However, despite decades of intense investigation, 
an effective therapeutic regimen for advanced disease is still lacking.
With the large scale sequencing of the human genome and breakthroughs in can-
cer genetics among all malignancies, there is tremendous enthusiasm for compounds 
that inhibit speciﬁ  c cellular targets. Imatinib mesylate, which selectively inactivates 
a class of enzymes known as tyrosine kinases, is one of the best examples of transla-
tional medicine in recent history (Druker 2002). Given its potent and highly speciﬁ  c 
mechanism of action, imatinib mesylate has become the standard of treatment for 
patients with BCR-ABL-associated chronic myelogenous leukemia (CML) among 
other cancers with activated tyrosine kinases. It is important to note, however, that 
none of the success of imatinib mesylate could have been possible without the early 
recognition that CML is associated with the Philadelphia chromosome and is geneti-
cally driven by a single translocation that juxtaposes the BCR gene with the ABL 
tyrosine kinase. Thus, underlying genetic insight is now viewed as a prerequisite for 
drug development. With imatinib mesylate as a model, there is general excitement in 
oncologic therapeutics that a full molecular disclosure of affected genetic targets will, 
in time, lead to previously unanticipated approaches for all cancers.Biologics: Targets & Therapy 2007:1(4) 408
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In the post-genomic era, our understanding of the 
molecular biology of melanoma has also increased dramati-
cally. Unlike CML however, advanced melanoma has yet to 
yield to molecular therapeutics.
Melanoma is a form of skin cancer that emanates from 
melanocytes, which are cells highly specialized in the for-
mation and transfer of melanin pigment. In their normal 
function, melanocytes provide the pigment that gives rise to 
the color of the skin, hair and eyes. They originate embryo-
logically from neural crest progenitors that ultimately migrate 
to the epidermis and hair follicles where they terminally 
differentiate and principally reside. Keratinocytes, which 
also reside in the epidermis and outnumber melanocytes by 
a ratio of about 10:1, release factors, which help promote 
the survival, differentiation, proliferation and motility of 
melanocytes (Gray-Schopfer, Wellbrock et al 2007). These 
growth factors bind to speciﬁ  c receptors at the cell surface 
and generate an intracellular message which ultimately leads 
to transcriptional changes and physiological responses, such 
as proliferation and survival. This entire cellular process is 
termed “signal transduction” and is mediated by a set of 
enzymes aimed at catalytically amplifying a small signal 
which emerges from the growth factor receptor. In the past 
few decades, much has been learned about growth signaling 
at the cellular and molecular levels and it has become clear 
that many of the participating molecules are in fact oncogenes 
in cancer, including melanoma. Recent insights into mela-
noma at the molecular level have demonstrated a stepwise 
progression of genetic hits that transforms a normal melano-
cyte or nevus into a primary and then metastatic melanoma 
(Bennett 2003). Multiple tumor-promoting events, including 
activation of oncogenes and inactivation of tumor suppressor 
genes, lead pigment cells through this transition.
One growth factor pathway that has garnered considerable 
attention in the last few years has been the RAS-BRAF-
MAPK-ERK signaling cascade. Much of the attention sur-
rounding this pathway in human melanoma focuses on the 
fact that in virtually all cases, there is an alteration at some 
level in the RAS signaling cascade (Haluska et al 2006). 
One component of this cascade, the BRAF protein kinase, is 
in fact the most frequently mutated oncogene in melanoma 
(Haluska et al 2006). Because of this, the BRAF molecule 
is a particularly appealing target for therapy, and indeed 
several biologic agents have been developed speciﬁ  cally 
for the purpose of affecting BRAF (Flaherty 2006). In this 
review our aim is to describe the current understanding of 
the most notable signaling cascade involved in melanoma, ie, 
the RAS/MAP kinase pathway, and to focus on the various 
molecules as they have been identiﬁ  ed or noted as potential 
therapeutic targets.
The RAS signaling pathway
RAS
Historically, the rat sarcoma (RAS) virus homologue was 
the ﬁ  rst oncogene to be described in human cancer (Der et al 
1982). In cancer, the most commonly mutated members of the 
RAS superfamily include HRAS, KRAS and NRAS. The RAS 
proteins are small (21 kilodalton) G-proteins that are active 
with bound GTP and inactive with bound GDP. Although 
the GTP can self-hydrolyze, there is a class of enzymes 
termed GAPs (GTPase activating proteins) that facilitate 
this hydrolysis and terminate RAS activity.
Oncogenic lesions introduce changes in the primary 
sequence of RAS so that the protein is constitutively active. 
By 1990, studies had identiﬁ  ed NRAS mutations in a frac-
tion of melanomas (Dicker et al 1990) thereby establishing a 
critical link between growth factor signaling and melanocytic 
tumors. Two decades later, the RAS pathway still remains 
one of the most investigated pathways in human cancer (Solit 
et al 2006), including melanoma, and our current under-
standing suggests that several possible mutations along this 
cascade lead to tumor-promoting physiology.
Although RAS proteins are frequently mutated in 
cancer, there is preferential targeting of speciﬁ  c family 
members in different tumor types. For melanomas, NRAS 
is mutated to a much greater extent than either KRAS or 
HRAS (Hocker and Tsao 2007; Tsao, Goel et al 2004). The 
basis for this speciﬁ  city is currently unknown but recent data 
suggest that NRAS may have unique functions in melano-
cytes that involve another oncogene, MYC (Whitwam et al 
2007). In a recent meta-analysis of all mutations reported 
in melanoma, NRAS was found to be mutated in 26.4% of 
all uncultured cutaneous melanoma specimens (N = 1064 
screened) (Hocker and Tsao 2007). Interestingly, a set of 
three NRAS mutations, NRASGly12Asp, NRASGln61Arg and 
NRASGln61Lys, accounted for 82% of the 255 substitutions 
at the NRAS locus.
RAF
A downstream effector of RAS is RAF (Figure 1) – a family of 
protein kinases which includes the sequentially homologous 
A-Raf, B-Raf and C-Raf proteins. RAF kinases are serine/
threonine phosphotransferases that initiate the mitogenic 
cascade which eventually converges on the ERKs. The ERKs 
then modulate gene expression through phosphorylation of 
transcription factors such as Jun, Elk1, c-Ets1/2, Stat 1/3, Biologics: Targets & Therapy 2007:1(4) 409
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or Myc. Not surprisingly, since both NRAS and BRAF are 
frequently activated in melanocytic tumors, ERKs has been 
shown to be phosphorylated, and therefore active, in up to 
90% of human melanomas (Cohen et al 2002).
Through a large systematic genetic screen of mutations 
in cancer, Davies et al identiﬁ  ed BRAF as a common onco-
gene in many cancers, particularly melanoma (Davies et al 
2002). In our meta-analysis of 1336 uncultured cutaneous 
melanomas, we found that BRAF mutations were reported 
in 42.4% of the tumors (Hocker and Tsao 2007). Even more 
striking than NRAS, one mutation, the BRAFV600E variant, 
accounts for nearly all of the reported changes in BRAF. 
This one mutation appears to release BRAF from an inac-
tive conformation thereby activating the kinase (Wan et al 
2004). It is important to note, however, that BRAF muta-
tions are not sufﬁ  cient to induce melanoma since many 
benign acquired nevi also harbor BRAF alterations (Uribe 
et al 2003). The emerging view of RAS-BRAF-MAPK 
signaling pathway is becoming increasingly intricate with 
multiple players acting at various levels, and it seems clear 
that at least some aspects of tumorigenicity are conferred 
through this pathway.
The RAF kinase signaling molecules have been shown 
to be involved in a variety of cellular processes, such as 
growth, proliferation, survival, differentiation and trans-
formation (Schreck and Rapp 2006). Despite the fact that 
much is known about the function of these molecules, there 
remains a substantial gap in the complete understanding. 
Some key ﬁ  ndings suggest that RAF signaling is important 
in the activation of NF-κB, and it is widely believed that 
the NF-κB transcription factor is an important mediator of 
antiapoptotic, proliferative, metatstatic, and proangiogenic 
effects, primarily through its induction of gene expression of 
proteins critical to these activities (Mayo et al 1997; Sosman 
and Puzanov 2006).
MAPK/ERK kinase (MAP kinase kinase)
The RAF kinases phosphorylate MEK thereby continuing the 
signaling stream. There have been no reports of MEK muta-
tions in melanoma, although mutagenic activation of NRAS 
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Figure 1 The RAS/MAP kinase signaling pathway. A growth factor binds to its cognate receptor tyrosine kinase (RTK), along with a transductive complex, which then activates RAS 
through an exchange of GTP for bound GDP. Active RAS then recruits inactive cytosolic BRAF to the membrane and activates BRAF.   Active BRAF in turn phosphorylates MEK 
thereby activating this MAPK kinase to phosphorylate and activate the ERKs.   Active ERK then translocates to the nucleus where it phosphorylates and regulates transcription 
factors, such as ELK. BRAF is mutated in about 60% of melanomas while NRAS is mutated in an additional 20%; the two events are functionally overlapping and thus genetically 
exclusive. The RTK, KIT, is mutated or ampliﬁ  ed in about 40% of acral and mucosal melanomas. The various inhibitors are shown in red boxes.
Abbreviations: MM, malignant melanoma; NM, nodular melanoma; SSM, superﬁ  cial spreading melanoma.Biologics: Targets & Therapy 2007:1(4) 410
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or BRAF is probably sufﬁ  cient to fully stimulate the MAP 
kinase signaling stream as in most tumors. The BRAFV600E 
mutation directly leads to activation of MEK although other 
mutations in BRAF appear to indirectly activate ERK through 
CRAF and not MEK (Wan et al 2004).
Extracellular signal regulated kinase 
(ERKs)/MAP kinase
The ERKs were originally cloned by Melanie Cobb and col-
leagues in 1991 through traditional biochemical strategies 
(Boulton and Cobb 1991; Boulton et al 1991). The ERKs 
comprise a family of protein kinases at 42/44 kilodaltons 
and are themselves activated by phosphorylation. With the 
development of antibodies speciﬁ  c for phospho-ERKs, it has 
become possible to gauge the activity of ERKs, and therefore 
MAP kinase signaling, in tissues without relying on actual 
enzymatic assays.
In melanoma, ERK activity has been shown to increase 
from early- to advanced-stage disease (Satyamoorthy et al 
2003). An attractive hypothesis is that NRAS or BRAF 
mutagenesis, which occurs upstream of ERK, is primarily 
responsible for the observed ERK activation. However, since 
BRAF mutations have been reported in nevi and yet ERKs 
are activated in only a minority of these specimens (Cohen 
et al 2002), other regulatory mechanisms must be in place to 
minimize unwanted MAP kinase stimulation. Notwithstand-
ing, strong evidence supports the contention that oncogenic 
BRAF mutations, most prevalently BRAFV600E (Brose et al 
2002) eventuate in overactivation of MEK/ERK, which 
maintains the transformed phenotype in malignant melanoma 
(Eisen et al 2006).
Growth factor receptors
The general dogma of RAS-RAF-MEK signaling posits that 
along with multiple other molecules (more than 70, partici-
pating at both the nuclear and nonnuclear level) (Schreck 
and Rapp 2006), the mitogenic cascade follows a fairly 
orderly sequence beginning at the cell surface with receptor 
tyrosine kinases (RTKs). In melanocytes, it is thought that 
the primary growth factors involved in this pathway include 
stem-cell factor (SCF), hepatocyte growth factor (HGF), and 
ﬁ  broblast growth factor (Gray-Schopfer, Wellbrock et al 
2007). The growth factors, in turn, through engagement 
of their speciﬁ  c RTKs, activate RAS, which subsequently 
triggers the cascade described above. This molecular game 
of “tag” serves to amplify the limited growth factor signal 
that is triggered at the extracellular membrane. For example, 
if one RAS molecule activates two RAF molecules, which 
in turn stimulates two MEK molecules each, then there is a 
4-fold ampliﬁ  cation of the RAS-initiated signal.
There is a subset of melanomas, primarily those occur-
ring on mucosal membranes, acral skin (palms of the hands, 
soles of the feet, and nail bed), and skin with chronic sun-
induced damage in which BRAF and NRAS mutations are 
only infrequently seen. These melanomas more frequently 
have mutations in KIT, the RTK for SCF (Curtin et al 2006). 
In a study by Bastian and coworkers, examination of 102 
primary melanomas revealed mutations and/or copy number 
increases of KIT in 39% of mucosal, 36% of acral, and 28% 
of melanomas on chronically sun-damaged skin, but not in 
any (0%) melanomas on skin without chronic sun damage; 
79% of the KIT mutations in melanoma resulted in increased 
KIT protein levels. These results clearly show that KIT is 
a bona ﬁ  de oncogene in melanoma. Interestingly, germline 
mutations in KIT (Tomita 1994) and the microphthalmia 
transcription factor (MITF) (Steingrimsson et al 2004) lead 
to disorders of pigment cell development while somatic 
activation of both KIT and MITF (Garraway, Widlund 
et al 2005) have been demonstrated in pigment cell tumors. 
These ﬁ  ndings suggest that tumors, including melanomas, 
undergo a phenomenon of “lineage” addiction (Garraway, 
Weir et al 2005).
The KIT RTK has been shown to function in signal 
transduction in several cell types including mast cells, 
melanocytes, hematopoietic stem cells, germ cells, and Cajal 
cells (Hussein 2006). Since KIT mutations have been shown 
to play an important role in several human malignancies, 
notably breast cancer (Roussidis et al 2007), gastrointestinal 
stromal tumors (Fletcher and Rubin 2007), mastocytosis 
(Gotlib 2006), and others, vigorous efforts have unfolded at 
treatment targeting this factor.
RAS pathway therapeutic targets 
for melanoma
To date, the clinical trials using pharmacological agents 
aimed at the treatment of melanoma have been frankly dis-
couraging. There are currently at least 18 drugs being studied 
at various phases for the targeted treatment of melanoma 
(Gray-Schopfer, Wellbrock et al 2007).
RAS inhibitors
Given the widespread prevalence of RAS mutations in 
cancer, this oncogene represents an ideal target for inhibi-
tion. However, the only agents that have been evaluated in 
clinical trials to alter RAS activity are the farnesyltransferase 
inhibitors (FTIs) (Flaherty 2006). At the molecular level, Biologics: Targets & Therapy 2007:1(4) 411
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it is believed that these FTIs impair the posttranslational 
modification of the RAS proteins, which consequently 
prevents their membrane localization, an event required for 
signaling activity (Johnston 2001).
These compounds have been studied extensively, and 
the diseases in which attempts have been made or are cur-
rently being studied include cancers as varied as leukemia, 
breast, pancreas, and glioma, as well as other diseases 
including progeria and neuroﬁ  bromatosis (current search for 
“farnesyltransferase inhibitors” in Clinicaltrials.gov, 2007). 
So far there has been no clinical efﬁ  cacy demonstrated. One 
FTI, SCH66336 (lonafarnib), inhibited melanoma growth in 
vitro although it has yet to be vigorously tested in melanoma 
trials (Smalley and Eisen 2003). However, the collective 
experience with lonafarnib in Phase III trials for other 
cancers has been generally disappointing (Morgillo and Lee 
2006). Tipifarnib (R115777) is an oral nonpeptidomimetic 
FTI that also showed promise in early Phase I and II trials; 
however, subsequent Phase II and III trials of tipifarnib as 
monotherapy for breast, colorectal, lung (both non-small 
cell and small cell), brain, pancreatic and urothelial cancers, 
have all demonstrated tipifarnib’s lack of signiﬁ  cant efﬁ  cacy 
(Mesa 2006).
RAF inhibitors
Sorafenib (BAY 43-9006, Nexavar®, Bayer Pharmaceuticals 
Corporation, West Haven, CT, USA) is an orally available 
multikinase inhibitor with effects on tumor-cell proliferation 
and angiogenesis (Escudier et al 2007). It was ﬁ  rst identiﬁ  ed 
as an inhibitor of RAF kinase (C-RAF  B-RAF) (Sosman 
and Puzanov 2006; Wilhelm et al 2004), but then later found 
to also inhibit vascular endothelial growth factor receptors 
(VEGFR) 1, 2, and 3; platelet-derived growth factor recep-
tor β (PDGFRβ); FMS-like tyrosine-kinase 3 (Flt-3); c-Kit 
protein (c-kit); and RET receptor tyrosine kinases (Carlom-
agno et al 2006; Escudier et al 2007; Wilhelm et al 2004). 
In vitro studies have shown that sorafenib induces cell cycle 
arrest and apoptosis in melanoma cell lines through MAPK 
activity inhibition (Gray-Schopfer, Karasarides et al 2007). 
Speciﬁ  c interference of the BRAFV600E mRNA by RNAi also 
leads to melanoma cell death suggesting that these cells are 
“addicted” to the BRAF oncogene (Hingorani et al 2003).
Sorafenib has been granted FDA approval for treatment of 
advanced clear-cell renal cell carcinoma based on a random-
ized, placebo-controlled trial demonstrating prolongation of 
progression-free survival (Escudier et al 2007). Additionally, 
a phase II randomized trial was discontinued due to superior 
efﬁ  cacy of sorafenib compared to placebo in metastatic 
renal cell carcinoma (Ratain et al 2006). Both of these trials 
demonstrated only modest beneﬁ  ts, but given the fact that 
renal cell carcinoma has notoriously been recalcitrant to all 
treatment modalities, these studies represented signiﬁ  cant 
breakthroughs. It should be noted that mutations of RAF 
are absent in renal cell carcinoma, and it is therefore likely 
that the activity of sorafenib in this disease is mediated by 
VEGF inhibition.
Clinical trials of sorafenib in melanoma were initiated 
with great hope and anticipation given its known and puta-
tive mechanisms of action (Beeram et al 2005; Karasarides 
et al 2004; Panka et al 2006; Rodriguez-Viciana et al 2005; 
Strumberg 2005; Wilhelm et al 2004). In a Phase II discon-
tinuation trial of 37 metastatic melanoma patients (Eisen et al 
2006), there was one objective response and six patients who 
had stable disease. In a phase I/II study, the combination of 
sorafenib with carboplatin and paclitaxel was associated with 
an objective response rate of 37%, substantially higher than 
the response rates historically reported with chemotherapy 
for melanoma (Flaherty et al 2004).
Based on these ﬁ  ndings, several randomized trials of 
chemotherapy with or without sorafenib have been initi-
ated. In a phase III study of 270 patients who had received 
prior chemotherapy for metastatic melanoma, the addition 
of sorafenib to carboplatin and paclitaxel failed to prolong 
progression-free survival. A similar trial in patients with no 
prior chemotherapy exposure is ongoing, as is a trial with 
the oral alkylating agent, temozolomide, in patients with 
brain metastases from melanoma (Amaravadi et al 2006). At 
present, the role of sorafenib in the treatment of advanced 
melanoma remains undeﬁ  ned, and it is not clear that BRAF 
mutational status predicts responsiveness to this agent. 
Reported adverse effects of sorafenib include hypertension 
(Veronese et al 2006), hand-foot syndrome, vasculitis (Chung 
et al 2006), rash, erythema multiforme (Macgregor et al 
2007), diarrhea and fatigue (Hahn and Stadler 2006).
Given the broad range of cancers that exhibit mutations 
in BRAF, there is intense interest in RAF inhibition as cancer 
therapy. Outlined in Table 1 is a list of compounds that are 
currently under development as anti-RAF agents. Several 
of these agents inhibit BRAF more potently and selectively 
than sorafenib.
MEK inhibitors
Using small-molecule inhibitors of MEK and an integrated 
genetic and pharmacologic analysis, Solit et al found that 
mutation of BRAF predicts sensitivity to MEK inhibition 
when compared to either ‘wild-type’ cells or cells with a RAS Biologics: Targets & Therapy 2007:1(4) 412
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mutation (Solit et al 2006). This inhibition may be partially 
mediated by downregulation of cyclin D1 protein expression 
and the induction of G1 arrest.
One MEK inhibitor, CI-1040, has entered clinical trials. 
In a Phase I study of 77 patients with a variety of advanced 
cancers (Lorusso et al 2005), 1 partial response was achieved 
in a patient with pancreatic cancer and 19 patients (28%) 
achieved stable disease lasting a median of 5.5 months 
(range, 4 to 17 months) with CI-1040. Although both target 
suppression and antitumor activity were demonstrated in this 
phase I study, clinical response was limited.
Another potent and selective inhibitor of MEK, 
AZD6244, has demonstrated activity against BRAF-mutant 
melanoma both in vitro and in vivo. It has completed phase 
I testing and is currently being evaluated in a randomized 
phase II trial in advanced melanoma.
KIT inhibitors
The tyrosine kinase inhibitor, imatinib mesylate, potently 
inhibits KIT and has been approved for treatment of gas-
trointestinal stromal tumors (Schnadig and Blanke 2006) 
and chronic myleogenous leukemia, as described above. 
In two Phase II studies of 26 and 18 metastatic melanoma 
patients, respectively, imatinib mesylate showed little clinical 
efﬁ  cacy (Ugurel et al 2005; Wyman et al 2006). However, 
based on the recognition that acral lentiginous and mucosal 
melanomas frequently harbor ampliﬁ  cations or mutations 
of KIT, a Phase II trial of imatinib mesylate (NIH Clinical 
Trial number NCT00424515) has been initiated for patients 
with these subtypes of melanoma.
Conclusion
The dramatic successes achieved with targeted therapies in 
some cancers, notably imatinib mesylate in chronic myelog-
enous leukemia and gastrointestinal stromal tumors, have 
not been observed in melanoma. However, there are myriad 
new agents targeting the MAP kinase pathways either in 
preclinical development or in clinical trials. Agents target-
ing BRAF and MEK will undoubtedly continue to undergo 
intensive evaluation in clinical trials for melanoma in the 
next few years.
While mutations in the MAP kinase signaling cascade 
are found in the majority of melanomas, numerous other 
dysregulated processes contribute to the malignant pheno-
type, including the PI3-kinase/AKT pathway, and regulators 
of apoptosis and cell cycle control. Given the complex and 
heterogeneous genetic properties of melanomas, a “person-
alized” treatment regimen will likely involve cocktails of 
highly targeted therapies aimed at various pathways.
Acknowledgments
This work was supported in part by grants from the National 
Institutes of Health, American Cancer Society and Depart-
ment of Defense (to HT).
References
Phase III Trial of Nexavar in patients with advanced melanoma does not 
meet primary endpoint. Press Release published by Onyx Pharma-
ceuticals, Inc. Accessed 12/4/2006. http://www.onyx-pharm.com/wt/
page/pr_1165242111.
Amaravadi RK, Schuchter LM, Kramer A, et al. 2006. 2006 ASCO 
Annual Meeting Proceedings Part I. Journal of Clinical Oncology, 
24(18S):8009.
Table 1 Current table of RAF kinase inhibitors
Molecule Developer  Study  phase  References
sorafenib/BAY 43-9006/  Bayer/Onyx  III  (Eisen et al 2006; Strumberg 2005; 
Nexavar®      Wilhelm and Chien 2002; 
      Wilhelm et al 2004)
AAL881  Novartis  Preclinical  (Ouyang et al 2006)
RAF-265  Novartis  I  (Amiri et al 2006; Stuart et al 2006; 
      Tsai et al 2006)
Compound 2  GlaxoSmithKline  Preclinical  (Hall-Jackson et al 1999)
LBT613  Novartis  Preclinical  (Khire et al 2004)
L-779450  Merck  Preclinical  (Hall-Jackson et al 1999), 
      (Heimbrook et al 1998)
Omega-carboxypyridyl  Bayer  Preclinical  (Lackey et al 2000)
PLX4032  Plexxikon  I  (Venetsanakos et al 2006)
SB-590885 (33)  GlaxoSmithKline  Preclinical  (Takle et al 2006)
X-6-(3 acetamidophenyl)   CCT, Sutton, UK  Preclinical  (Niculescu-Duvaz et al 2006)
pryrazines
ZM 336372  AstraZeneca  Precinical  (Heimbrook et al 1998)
Adapted from Schreck and Rapp (2006) and Gray-Schopfer, Wellbrock et al (2007).Biologics: Targets & Therapy 2007:1(4) 413
RAS/MAP kinase pathway in melanoma biology and therapeutics
Amiri P, Aikawa M, Dove J, et al. 2006. CHIR-265 is a potent selective 
inhibitor of c-Raf/B-Raf/mutB-Raf that effectively inhibits proliferation 
and survival of cancer cell lines with Ras/Raf pathway mutations. 97th 
AACR annual meeting. Washington, DC.
Beeram M, Patnaik A, Rowinsky EK. 2005. Raf: a strategic target for thera-
peutic development against cancer. J Clin Oncol, 23:6771–90.
Bennett DC. 2003. Human melanocyte senescence and melanoma suscep-
tibility genes. Oncogene, 22:3063–9.
Boulton TG, Cobb MH. 1991. Identiﬁ  cation of multiple extracellular 
signal-regulated kinases (ERKs) with antipeptide antibodies. Cell 
Regul, 2:357–71.
Boulton TG, Nye SH, Robbins DJ, et al. 1991. ERKs: a family of protein-
serine/threonine kinases that are activated and tyrosine phosphorylated 
in response to insulin and NGF. Cell, 65:663–75.
Brose MS, Volpe P, Feldman M, et al. 2002. BRAF and RAS mutations in 
human lung cancer and melanoma. Cancer Res, 62:6997–7000.
Carlomagno F, Anaganti S, Guida T, et al. 2006. BAY 43-9006 inhibition 
of oncogenic RET mutants. J Natl Cancer Inst, 98:326–34.
Chung NM, Gutierrez M, Turner ML. 2006. Leukocytoclastic vasculitis 
masquerading as hand-foot syndrome in a patient treated with sorafenib. 
Arch Dermatol, 142:1510–11.
Cohen C, Zavala-Pompa A, Sequeira JH, et al. 2002. Mitogen-actived 
protein kinase activation is an early event in melanoma progression. 
Clin Cancer Res, 8:3728–33.
Curtin JA, Busam K, Pinkel D, et al. 2006. Somatic activation of KIT in 
distinct subtypes of melanoma. J Clin Oncol, 24:4340–6.
Davies H, Bignell GR, Cox C, et al. 2002. Mutations of the BRAF gene in 
human cancer. Nature, 417:949–54.
Der CJ, Krontiris TG, Cooper GM. 1982. Transforming genes of human 
bladder and lung carcinoma cell lines are homologous to the ras genes 
of Harvey and Kirsten sarcoma viruses. Proc Natl Acad Sci USA, 
79:3637–40.
Dicker AP, Volkenandt M, Albino AP. 1990. Mutational analysis of human 
NRAS genes in malignant melanoma: rapid methods for oligonucleotide 
hybridization and manual and automated direct sequencing of products 
generated by the polymerase chain reaction. Genes Chromosomes 
Cancer, 1:257–69.
Druker BJ. 2002. Perspectives on the development of a molecularly targeted 
agent. Cancer Cell, 1:31–6.
Eisen T, Ahmad T, Flaherty KT, et al. 2006. Sorafenib in advanced 
melanoma: a Phase II randomised discontinuation trial analysis. Br J 
Cancer, 95:581–6.
Escudier B, Eisen T, Stadler WM, et al. 2007. Sorafenib in advanced clear-
cell renal-cell carcinoma. N Engl J Med, 356:125–34.
Flaherty KT. 2006. Chemotherapy and targeted therapy combinations in 
advanced melanoma. Clin Cancer Res, 12:2366s–2370s.
Flaherty KT, Brose M, Schuchter L, et al. 2004. 2004 ASCO Annual Meet-
ing Proceedings (Post-Meeting Edition). Journal of Clinical Oncology, 
22(14S):7507.
Fletcher JA, Rubin BP. 2007. KIT mutations in GIST. Curr Opin Genet 
Dev, 17:3–7.
Garraway LA, Weir BA, Zhao X, et al. 2005. “Lineage addiction” in human 
cancer: lessons from integrated genomics. Cold Spring Harb Symp 
Quant Biol, 70:25–34.
Garraway LA, Widlund HR, Rubin MA, et al. 2005. Integrative genomic 
analyses identify MITF as a lineage survival oncogene ampliﬁ  ed in 
malignant melanoma. Nature, 436:117–22.
Gotlib J. 2006. KIT mutations in mastocytosis and their potential as thera-
peutic targets. Immunol Allergy Clin North Am, 26:575–92.
Gray-Schopfer V, Wellbrock C, Marais R. 2007. Melanoma biology and 
new targeted therapy. Nature, 445:851–7.
Gray-Schopfer VC, Karasarides M, Hayward R, et al. 2007. Tumor necrosis 
factor-alpha blocks apoptosis in melanoma cells when BRAF signaling 
is inhibited. Cancer Res, 67:122–9.
Hahn O, Stadler W. 2006. Sorafenib. Curr Opin Oncol, 18:615–21.
Hall-Jackson CA, Eyers PA, Cohen P, et al. 1999. Paradoxical activation 
of Raf by a novel Raf inhibitor. Chem Biol, 6:559–68.
Haluska FG, Tsao H, Wu H, et al. 2006. Genetic alterations in signaling 
pathways in melanoma. Clin Cancer Res, 12:2301s–2307s.
Heimbrook D, Huber H, Stirdivant S, et al. 1998. Identiﬁ  cation of potent, 
selective kinase inhibitors of Raf. American Association of Cancer 
Research, p. 558.
Hingorani SR, Jacobetz MA, Robertson GP, et al. 2003. Suppression of 
BRAF(V599E) in human melanoma abrogates transformation. Cancer 
Res, 63:5198–202.
Hocker T, Tsao H. 2007. Ultraviolet radiation and melanoma: a systematic 
review and analysis of reported sequence variants. Hum Mutat.
Hussein MR. 2006. Expression of KIT receptor tyrosine kinase protein in 
normal human skin: Preliminary observations. Cell Biol Int.
Jemal A, Siegel R, Ward E, et al. 2007. Cancer statistics, 2007. CA Cancer 
J Clin, 57:43–66.
Johnston SR. 2001. Farnesyl transferase inhibitors: a novel targeted tnerapy 
for cancer. Lancet Oncol, 2:18–26.
Karasarides M, Chiloeches A, Hayward R, et al. 2004. B-RAF is a thera-
peutic target in melanoma. Oncogene, 23:6292–8.
Khire UR, Bankston D, Barbosa J, et al. 2004. Omega-carboxypyridyl sub-
stituted ureas as Raf kinase inhibitors: SAR of the amide substituent. 
Bioorg Med Chem Lett, 14:783–6.
Lackey K, Cory M, Davis R, et al. 2000. The discovery of potent cRaf1 
kinase inhibitors. Bioorg Med Chem Lett, 10:223–6.
Lorusso PM, Adjei AA, Varterasian M, et al. 2005. Phase I and pharma-
codynamic study of the oral MEK inhibitor CI-1040 in patients with 
advanced malignancies. J Clin Oncol, 23:5281–93.
Macgregor JL, Silvers DN, Grossman ME, et al. 2007. Sorafenib-induced 
erythema multiforme. J Am Acad Dermatol.
Mayo MW, Wang CY, Cogswell PC, et al. 1997. Requirement of NF-kappaB 
activation to suppress p 53-independent apoptosis induced by oncogenic 
Ras. Science, 278:1812–15.
Mesa RA. 2006. Tipifarnib: farnesyl transferase inhibition at a crossroads. 
Expert Rev Anticancer Ther, 6:313–19.
Morgillo F, Lee HY. 2006. Lonafarnib in cancer therapy. Expert Opin 
Investig Drugs, 15:709–19.
Niculescu-Duvaz I, Roman E, Whittaker SR, et al. 2006. Novel inhibitors 
of B-RAF based on a disubstituted pyrazine scaffold. Generation of a 
nanomolar lead. J Med Chem, 49:407–16.
Ouyang B, Knauf JA, Smith EP, et al. 2006. Inhibitors of Raf kinase activity 
block growth of thyroid cancer cells with RET/PTC or BRAF mutations 
in vitro and in vivo. Clin Cancer Res, 12:1785–93.
Panka DJ, Wang W, Atkins MB, et al. 2006. The Raf inhibitor BAY 43-9006 
(Sorafenib) induces caspase-independent apoptosis in melanoma cells. 
Cancer Res, 66:1611–19.
Pickle LW, Hao Y, Jemal A, et al. 2007. A new method of estimating United 
States and state-level cancer incidence counts for the current calendar 
year. CA Cancer J Clin, 57:30–42.
Ratain MJ, Eisen T, Stadler WM, et al. 2006. Phase II placebo-controlled 
randomized discontinuation trial of sorafenib in patients with metastatic 
renal cell carcinoma. J Clin Oncol, 24:2505–12.
Rodriguez-Viciana P, Tetsu O, Oda K, et al. 2005. Cancer targets in the Ras 
pathway. Cold Spring Harb Symp Quant Biol, 70:461–7.
Roussidis AE, Theocharis AD, Tzanakakis GN, et al. 2007. The Impor-
tance of c-Kit and PDGF Receptors as Potential Targets for Molecular 
Therapy in Breast Cancer. Curr Med Chem, 14:735–43.
Satyamoorthy K, Li G, Gerrero MR, et al. 2003. Constitutive mitogen-activated 
protein kinase activation in melanoma is mediated by both BRAF muta-
tions and autocrine growth factor stimulation. Cancer Res, 63:756–9.
Schnadig ID, Blanke CD. 2006. Gastrointestinal stromal tumors: imatinib 
and beyond. Curr Treat Options Oncol, 7:427–37.
Schreck R, Rapp UR. 2006. Raf kinases: oncogenesis and drug discovery. 
Int J Cancer, 119:2261–71.
Smalley KS, Eisen TG. 2003. Farnesyl transferase inhibitor SCH66336 is 
cytostatic, pro-apoptotic and enhances chemosensitivity to cisplatin in 
melanoma cells. Int J Cancer, 105:165–75.
Solit DB, Garraway LA, Pratilas CA, et al. 2006. BRAF mutation predicts 
sensitivity to MEK inhibition. Nature, 439:358–62.Biologics: Targets & Therapy 2007:1(4) 414
Jarell et al
Sosman JA, Puzanov I. 2006. Molecular targets in melanoma from 
angiogenesis to apoptosis. Clin Cancer Res, 12:2376s–2383s.
Steingrimsson E, Copeland NG, Jenkins NA. 2004. Melanocytes and 
the microphthalmia transcription factor network. Annu Rev Genet, 
38:365–411.
Strumberg D. 2005. Preclinical and clinical development of the oral mul-
tikinase inhibitor sorafenib in cancer treatment. Drugs Today (Barc), 
41:773–84.
Stuart D, Aardalen K, Lorenzana E, et al. 2006. Characterization of a novel 
Raf kinase inhibitor that causes target dependent tumor regression in 
human melanoma xenografts expressing mutant B-Raf. 97th AACR 
annual meeting. Washington, DC.
Takle AK, Brown MJ, Davies S, et al. 2006. The identiﬁ  cation of potent 
and selective imidazole-based inhibitors of B-Raf kinase. Bioorg Med 
Chem Lett, 16:378–81.
Tomita Y. 1994. The molecular genetics of albinism and piebaldism. Arch 
Dermatol, 130:355–8.
Tsai J, Zhang J, Bremer R, et al. 2006. Development of a novel inhibitor of 
oncogenic B-RAF. 97th AACR annual meeting. Washington, DC.
Tsao H, Atkins MB, Sober AJ. 2004. Management of cutaneous melanoma. 
N Engl J Med, 351:998–1012.
Tsao H, Goel V, Wu H, et al. 2004. Genetic interaction between NRAS 
and BRAF mutations and PTEN/MMAC1 inactivation in melanoma. 
J Invest Dermatol, 122:337–41.
Ugurel S, Hildenbrand R, Zimpfer A, et al. 2005. Lack of clinical efﬁ  cacy 
of imatinib in metastatic melanoma. Br J Cancer, 92:1398–405.
Uribe P, Wistuba, II, Gonzalez S. 2003. BRAF mutation: a frequent event 
in benign, atypical, and malignant melanocytic lesions of the skin. 
Am J Dermatopathol, 25:365–70.
Venetsanakos E, Stuart D, Tan N, et al. 2006. CHIR-265, a novel inhibitor 
that targets B-Raf and VEGFR, shows efﬁ  cacy in a broad range of 
preclinical models. 97th AACR annual meeting. Washington, DC.
Veronese ML, Mosenkis A, Flaherty KT, et al. 2006. Mechanisms of hyper-
tension associated with BAY 43-9006. J Clin Oncol, 24:1363–9.
Wan PT, Garnett MJ, Roe SM, et al. 2004. Mechanism of activation of 
the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. 
Cell, 116:855–67.
Whitwam T, Vanbrocklin MW, Russo ME, et al. 2007. Differential 
oncogenic potential of activated RAS isoforms in melanocytes. 
Oncogene.
Wilhelm S, Chien DS. 2002. BAY 43-9006: preclinical data. Curr Pharm 
Des, 8:2255–7.
Wilhelm SM, Carter C, Tang L, et al. 2004. BAY 43-9006 exhibits broad 
spectrum oral antitumor activity and targets the RAF/MEK/ERK path-
way and receptor tyrosine kinases involved in tumor progression and 
angiogenesis. Cancer Res, 64:7099–109.
Wyman K, Atkins MB, Prieto V, et al. 2006. Multicenter Phase II trial of 
high-dose imatinib mesylate in metastatic melanoma: signiﬁ  cant toxicity 
with no clinical efﬁ  cacy. Cancer, 106:2005–11.